Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances
- The company’s non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates.
- Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings.
- INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity.
- The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety.
- INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery.
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies (https://nnw.fm/j0eyA ).
The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for those working on evidence-based approaches to substance use and behavioral health issues.
At the conference, INBS presented its system alongside its U.S. distribution partner SMARTOX. SMARTOX, founded in 2012, provides drug and alcohol testing services across a wide range of institutional settings in the United States. The firm offers a full-service model, including distribution, customer support, and program design.
INBS’s drug screening system, designed for forensic use in the United States, detects recent drug use by analyzing fingerprint sweat. It screens for cannabis, cocaine, methamphetamine, and opiates, producing results in under ten minutes.
INBS President and CEO Harry Simeonidis and Vice President of Global Sales Doug Heath were present at the event, joining SMARTOX’s Vice President of Sales and Marketing, Duffy Nabors, in demonstrating the system’s potential applications.
The system’s portability and ease of use are well-suited to environments where rapid screening and privacy are important, such as treatment courts, probation programs, and correctional settings. The fingerprint sweat-based system offers an alternative to traditional urine or saliva tests, with less need for invasive procedures or secure facilities.
Heath emphasized the importance of delivering “effective screening methods for justice-involved individuals,” particularly in programs focused on recovery and rehabilitation rather than incarceration. “The RISE conference represents a national effort to transform justice responses to substance use and mental health,” said Heath. “We’re proud to support SMARTOX in showcasing our solution and to contribute to the conversation around dignity, access, and effective screening methods for justice-involved individuals.”
The company’s attendance at RISE25 reflects its broader strategy to position the technology in the U.S. justice and public health sectors. Currently, the system is approved only for forensic use in the U.S., but INBS is seeking broader FDA clearance.
Outside the U.S., the company’s drug testing system is already deployed in sectors such as construction, manufacturing, transport, and drug treatment. In total, INBS reports more than 450 active accounts across 24 countries, reflecting growing global interest in rapid, on-site testing tools.
For INBS, the U.S. forensic market offers a testbed for its system, while regulatory progress may open up opportunities in other high-demand areas such as workplace safety and healthcare. The company’s participation in RISE25 provided a direct channel to policymakers, researchers, and court officials interested in more efficient screening methods.
For more information, visit the company’s website at https://ibs.inc.
NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at http://nnw.fm/INBS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- The company’s non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates.
- Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings.
- INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity.
- The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety.
- INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery.
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies (https://nnw.fm/j0eyA ).
The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for those working on evidence-based approaches to substance use and behavioral health issues.
At the conference, INBS presented its system alongside its U.S. distribution partner SMARTOX. SMARTOX, founded in 2012, provides drug and alcohol testing services across a wide range of institutional settings in the United States. The firm offers a full-service model, including distribution, customer support, and program design.
INBS’s drug screening system, designed for forensic use in the United States, detects recent drug use by analyzing fingerprint sweat. It screens for cannabis, cocaine, methamphetamine, and opiates, producing results in under ten minutes.
INBS President and CEO Harry Simeonidis and Vice President of Global Sales Doug Heath were present at the event, joining SMARTOX’s Vice President of Sales and Marketing, Duffy Nabors, in demonstrating the system’s potential applications.
The system’s portability and ease of use are well-suited to environments where rapid screening and privacy are important, such as treatment courts, probation programs, and correctional settings. The fingerprint sweat-based system offers an alternative to traditional urine or saliva tests, with less need for invasive procedures or secure facilities.
Heath emphasized the importance of delivering “effective screening methods for justice-involved individuals,” particularly in programs focused on recovery and rehabilitation rather than incarceration. “The RISE conference represents a national effort to transform justice responses to substance use and mental health,” said Heath. “We’re proud to support SMARTOX in showcasing our solution and to contribute to the conversation around dignity, access, and effective screening methods for justice-involved individuals.”
The company’s attendance at RISE25 reflects its broader strategy to position the technology in the U.S. justice and public health sectors. Currently, the system is approved only for forensic use in the U.S., but INBS is seeking broader FDA clearance.
Outside the U.S., the company’s drug testing system is already deployed in sectors such as construction, manufacturing, transport, and drug treatment. In total, INBS reports more than 450 active accounts across 24 countries, reflecting growing global interest in rapid, on-site testing tools.
For INBS, the U.S. forensic market offers a testbed for its system, while regulatory progress may open up opportunities in other high-demand areas such as workplace safety and healthcare. The company’s participation in RISE25 provided a direct channel to policymakers, researchers, and court officials interested in more efficient screening methods.
For more information, visit the company’s website at https://ibs.inc.
NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at http://nnw.fm/INBS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
